A new way to screen for more cancers

The Galleri® multi-cancer early detection test detects a cancer signal across more than 50 types of cancer.1,2 It’s now available to employees enrolled in a Premier Medical Plan and their spouse or domestic partner who meet eligibility requirements.

Check Eligibility

The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. Galleri should be used in addition to healthcare provider recommended screening tests.

Roger testimonial

The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. Galleri should be used in addition to healthcare provider recommended screening tests.

Key benefits of the Galleri test

hourglass icon

Early cancer detection

Detects many cancers not commonly screened for today, to allow for earlier treatment.1

stethoscope icon

Testing with ease

Completed with a simple blood draw.

blue test result icon

Actionable results

If a cancer signal is found, the results can point to where in the body the cancer is coming from with high accuracy.

The Galleri test is a screening test and does not detect all cancers.
Further testing is needed to diagnose cancer if a signal is detected.

What is the Galleri test?

What is Galleri?

illustrated video poster of the Galleri test sitting on a table in an examination room with an anatomy poster on the wall behind it

Patient testimonial: Valerie

Who is eligible?

The Galleri test is offered as an annual, covered benefit to eligible US-based Qualcomm employees and their spouse/domestic partner, who are enrolled in a Qualcomm Premier Medical Plan. This test is available to individuals aged 50 and older, or aged 35 - 49 with certain risk factors.

Eligibility criteria:

  • US-based employees and their spouse/domestic partner
  • Enrolled in one of Qualcomm’s Premier Medical Plans (PPO or QDHP)
  • Aged 50 years old and older
  • Aged 35 - 49 with risk factors documented below
Black couple sitting at their kitchen table writing on a notepad with a cup of coffee and a tablet on the table in front of them

Galleri for Qualcomm

Galleri testing is available to eligible individuals through primary care providers at all Scripps Clinic and Scripps Coastal locations, and at the San Diego Qualcomm Health Centers.

You can request Galleri testing when you schedule your annual preventative visit. If you recently completed your annual preventative care visit, a separate appointment (virtual or in-person) must be scheduled to discuss and verify eligibility for the testing.

Please contact the Premier Plan Concierge at 844-884-7266 if you have questions or for help scheduling your visit.

Frequently Asked Questions

The Galleri test is offered as an annual, covered benefit to US.-based Qualcomm employees and their spouse/domestic partner, who are enrolled in a Qualcomm Premier Medical Plan, and are aged 50 and older, or aged 35 - 49 with certain risk factors, listed below.

Eligibility criteria (must meet all of the following):

  • US-based Employees and their Spouse/Domestic Partner
  • Enrolled in one of Qualcomm’s Premier Medical Plans (PPO or QDHP)
  • 50 years old and older

-OR-

  • 35-49 years old at least one of the following risk factors:
    • Cancer survivor who has completed treatment at least 3 years ago*
    • Currently smokes or quit smoking less than 10 years ago
    • Diagnosis of cirrhosis or chronic Hepatitis B or C infection
    • Infection with certain strains of HPV (e.g. HPV 16 or 18)
    • Known hereditary cancer syndrome
      • Confirmation or documentation of a gene mutation associated with increased cancer risk (e.g., Li-Fraumeni syndrome, Hereditary Breast and Ovarian Cancer syndrome [BRCA1/2], Lynch syndrome, CHEK2).

-OR-

  • 35-49 years old AND at least two of the following risk factors:
    • Documented genetic predisposition (germline variant)
    • First degree relative with cancer**
    • History of HIV infection
    • Current use of immunosuppressive therapies after organ transplantation
    • Diabetes
    • BMI
      • Female ≥ 30
      • Male ≥ 35

Use of Galleri is not recommended in individuals who are pregnant or undergoing active cancer treatment.

Only people who fit the eligibility criteria are covered by the Qualcomm benefit.

Family members who are interested in the test and do not meet eligibility criteria can learn more, and order Galleri, through a self-pay option at Galleri.com.

The Galleri test is prescription only. You can request the test when scheduling your annual preventive visit.

If you recently completed your annual preventive care visit, a separate appointment (virtual or in-person) must be scheduled to discuss and verify eligibility for the testing.

Please contact the Scripps Premier Plan Concierge team at 844-884-7266 Monday- Friday, 7 a.m. to 7 p.m. if you have questions, or for help scheduling your visit.

The cost of the Galleri test, blood draw, and laboratory fees are all covered under the Premier Plan benefit.

The test cost is covered annually for eligible employees and their spouse/dependent.

Yes, if you are not eligible for the benefit under Qualcomm’s program, you may use pre-tax dollars in your Health Care FSA or HSA to pay for the Galleri test on galleri.com. Contact your FSA/HSA administrator, OptumBank, if you have any questions by phone at (800) 243-5543 or by email at service.Qualcomm@optumbank.com.

GRAIL is a healthcare company focused on saving lives and improving health by pioneering new technologies for early cancer detection. GRAIL is the company that manufactures the Galleri multi-cancer early detection test. You may receive information or communications from GRAIL or Galleri about your benefit or the Galleri test.

Under Qualcomm’s benefit program, eligible employees and their spouse/domestic partner can receive the Galleri test as a covered benefit annually. Galleri screens for a “fingerprint” of many of the deadliest cancers before they become symptomatic. These cancers include those with no recommended screening tests today, such as pancreatic, ovarian, and liver cancers.1,2,3* 

  1. American Cancer Society. Cancer facts & figures 2022. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2022.html [GRAIL, LLC. Data on file: GA-2021-0065] 
    Assumes screening is available for all prostate, breast, cervical, and colorectal cancer cases and 43% of lung cancer cases (based on the estimated proportion of lung cancers that occur in screen-eligible individuals older than 40 years). 
  2. Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021 Sep;32(9):1167-77. doi: 10.1016/j.annonc.2021.05.806 
  3. US Preventive Services Task Force. A,B,C grade recommendations, cancer, screenings. [cited 2023 Oct 23]. https://www.uspreventiveservicestaskforce.org/uspstf/topic_search_results 

*Sensitivity in study participants — Pancreatic cancer: 83.7% overall (61.9% stage I, 60.0% stage II, 85.7% stage III, 95.9% stage IV); ovarian cancer: 83.1% overall (50.0% stage I, 80.0% stage II, 87.1% stage III, 94.7% stage IV); Liver/bile duct cancer: 93.5% overall (100% stage I, 70.0% stage II, 100% stage III, 100% stage IV).

Your employer only receives de-identified and aggregated information across all employees (e.g. how many tests have been requested) and will not receive individual results.

The Galleri test is a screening test for asymptomatic adults with an elevated risk for cancer, such as those aged 50 or older. Galleri detects a signal shared by multiple cancers; when a Cancer Signal is Detected, Galleri predicts Cancer Signal Origin to guide diagnostic evaluation.

The Galleri test looks for active cancer and does not predict future genetic risk for cancer. 

All cells in your body, including cancer cells, release DNA fragments into the bloodstream. These fragments are called cell-free DNA. The Galleri test screens your blood sample for cell-free DNA and identifies whether it comes from healthy or cancer cells. Cell-free DNA from cancer cells also contains information about the organ or tissue of origin. The process uses advanced technology and pattern recognition to detect a Cancer Signal and predict the Cancer Signal Origin. This information helps guide healthcare providers to perform a diagnostic evaluation for cancer.

Cancer risk increases for everyone as they age, regardless of family history—only 5% to 10% of cancers are inherited.

Age is the biggest risk factor for cancer. In fact, adults over age 50 are 13 times more likely to have cancer compared to people under the age of 50.

Galleri detects a signal shared by multiple cancers, in a clinical study, Galleri detected a signal shared by over 50 types of cancer —including some fast-spreading and deadly cancers responsible for approximately two-thirds of cancer deaths. The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur.

Most people who take the Galleri test will receive a “No Cancer Signal Detected” result. A “Cancer Signal Detected” result is expected in approximately 1% of Galleri tests in people over 50 years of age.

The Galleri test accuracy is measured through Positive Predictive Value and False Positive Rates.

  • Positive Predictive Value (PPV) is the probability that a person with a “Cancer Signal Detected” test result has cancer.
  • A False Positive is a test result that indicates that a person has a specific disease or condition when the person actually does not have the disease or condition.

In a recent study, the PPV was 43.1% for study participants with a Cancer Signal Detected result who were diagnosed with cancer. The False Positive Rate was 0.5% for participants without cancer. Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer.

No, Galleri is not a genetic risk assessment test. A genetic risk assessment is a one time measurement and assesses the future risk of developing cancer. Genetic tests may look at DNA and assess lifelong risk for cancer but cannot detect if a person currently has cancer.

The Galleri test looks for a signal associated with active cancer at the time of your blood draw. Regularly using the Galleri test, alongside recommended cancer screenings, can increase your chance of detecting cancer early.

No, the Galleri test is only commercially available in the US.

Contact Concierge at 844-887-7266 Monday-Friday, 7 a.m. to 7 p.m. for assistance with scheduling your annual physical and options for obtaining the Galleri test collection kit and blood draw locations.

Learn more about how your sample is processed at the GRAIL laboratory by watching this video.

Once you receive your sample collection kit, please do not break the quality seal on it. The collection kit should be opened by the trained technician who draws your blood sample. 

Store the kit at room temperature until your blood draw appointment. The contents are sensitive to extreme temperatures. For example, do not store the collection kit in a car.

The trained technician who draws your blood will pack and ship your sample back to the GRAIL laboratory for processing. Everything needed to complete the blood draw and return the sample is within the Galleri kit.

No, fasting is not required for the Galleri test.

Approximately 1.5 tablespoons (or about 20 mL) of blood in two tubes from a vein in your arm.

If you no longer wish to receive your Galleri results, contact GRAIL Customer Service by calling (833) 694‑2553.

Your sample will arrive at the GRAIL lab one to two days after your blood draw. Test results will be available about two weeks after your sample is received at the GRAIL lab. 

If you participated in an onsite blood draw sponsored by your employer results may take as long as three weeks.

Your test results can be requested by contacting GRAIL Customer Service by calling (833) 694‑2553.

The Galleri test detected a signal associated with cancer. This result will also include one or two predictions of the tissue type or organ associated with the cancer signal, called “Cancer Signal Origin.” 

Results should be interpreted by a healthcare provider. This test result is not a cancer diagnosis and requires follow-up diagnostic testing which may include lab work or imaging ordered by your healthcare provider. GRAIL also offers patients and providers additional support and resources if needed to help guide next steps. 

False positive and false negative results do occur.

The Galleri test looked for a cancer signal in your blood sample and did not find one. This result does not completely rule out the possibility of cancer. The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. Continue with routine cancer screenings your healthcare provider recommends. 

A Galleri result of No Cancer Signal Detected does not rule out cancer.

The Galleri test is intended to be used in addition to, and not replace, other cancer screening tests your healthcare provider recommends. Single-cancer screening tests are recommended because they have been proven to save lives by detecting cancer early. Using Galleri in addition to recommended single-cancer screenings can increase your chances of detecting cancer early, to allow for earlier treatment. 

Galleri does not detect a signal for all cancers and not all cancers can be detected in the blood.

A Cancer Signal Detected test result is not a cancer diagnosis. A Cancer Signal Detected result requires follow-up diagnostic testing which may include lab work or imaging ordered by your healthcare provider. GRAIL also offers patients and providers additional support and resources if needed to help guide next steps.

All results are automatically shared with the provider who ordered the test. If you would like us to fax your results to an additional healthcare provider, please contact Customer Service by calling (833) 694‑2553 to receive instructions on how to complete a results release form.

Get support

For questions about the Galleri test, please contact GRAIL Customer Service:

The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.

Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of No Cancer Signal Detected does not rule out cancer. A test result of Cancer Signal Detected requires confirmatory diagnostic evaluation by medically established procedures (e.g. imaging) to confirm cancer.

If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.

The GRAIL clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. The GRAIL clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.

  1. Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32(9):1167-77. DOI:https://doi.org/10.1016/j.annonc.2021.05.806.

  2. The Galleri test does not detect all cancers nor does it measure your genetic risk of developing cancer in the future. It should be used in addition to routine screening tests your healthcare provider recommends.